Insulet Corp (PODD) FinancialsPODDInsulet Corp

Insulet Corporation (PODD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is U.S.Omnipod, accounting for 67.9% of total sales, equivalent to $544.10M. Other significant revenue streams include International Omnipod and Drug Delivery. Understanding this composition is critical for investors evaluating how PODD navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Insulet Corporation maintains a gross margin of 70.18%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 16.15%, while the net margin is 11.85%. These profitability ratios, combined with a Return on Equity (ROE) of 26.02%, provide a clear picture of how effectively PODD converts its operational activities into shareholder value.

In the context of the broader market, PODD competes directly with industry leaders such as AVTR and BIO. With a market capitalization of $9.95B, it holds a leading position in the sector. When comparing efficiency, PODD's gross margin of 70.18% stands against AVTR's 31.73% and BIO's 53.12%. Such benchmarking helps identify whether Insulet Corporation is trading at a premium or discount relative to its financial performance.

Insulet reported a total revenue of $801.7 million in Q2 2026, with a gross margin of 70.18%. The net income for the same quarter was $95 million, reflecting a solid financial position despite recent stock price declines.